Skip to main content

Noyes Timothy P's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed May 3, 2024

Accession no.
0001415889-24-012234
Filed
May 3, 2024
Trade date
May 1, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $230.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Noyes Timothy PCIK 0001185035Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2024Common StockMOption exerciseAcquired+10,000$2.14+$21,40010,000Direct
May 1, 2024Common StockSSaleDisposed−9,035$20.34−$183,771.9965Direct
May 1, 2024Common StockSSaleDisposed−965$20.87−$20,139.550Direct
May 1, 2024Common StockSSaleDisposed−1,357$19.91−$27,017.870Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2024Common StockMOption exerciseDisposed−10,000$0.00$0353,381Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)